11.09.2019 | Brief Communication | Ausgabe 2/2020
New multifunctional AChE inhibitor drug prototypes protect against Aβ-induced memory deficit
- Zeitschrift:
- Neurological Sciences > Ausgabe 2/2020
Wichtige Hinweise
Electronic supplementary material
The online version of this article (https://doi.org/10.1007/s10072-019-04036-6) contains supplementary material, which is available to authorized users.
Paula M. Q. Bellozi, Alline C. Campos, Claudio Viegas Jr and Antônio C. P. de Oliveira contributed equally to this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abstract
Alzheimer’s disease (AD) is the most incident neurodegenerative disorder, characterized by accumulation of extracellular amyloid-β (Aβ), intracellular neurofibrillary tangles, and cognitive impairment. The current available treatments are mainly based on the use of reversible acetylcholinesterase (AChE) inhibitors, which only ameliorate the cognitive deficits. However, it is important to develop disease-modifying drugs with neuroprotective effects in order to hamper the progression of the disease. Here, we describe the effect of four promising new drugs with additional protective characteristics on AD-associated memory changes. C57Bl/6 mice treated with the compounds received an intra-hippocampal injection of Aβ1-40 and were submitted to the novel object recognition test, to evaluate memory recovery. All the compounds prevented memory loss. Compounds PQM-56 (4c) and PQM-67 (4g) showed the best profile of memory recovery, representing potential drug candidates for AD treatment.